E-Book, Englisch, 316 Seiten
Acute Endocrinology:
1. Auflage 2008
ISBN: 978-1-60327-177-6
Verlag: Humana Press
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
From Cause to Consequence
E-Book, Englisch, 316 Seiten
ISBN: 978-1-60327-177-6
Verlag: Humana Press
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
Autoren/Hrsg.
Weitere Infos & Material
1;Preface;5
2;Contents;6
3;Contributors;8
4;I ENDOCRINE DISEASES CAUSING POTENTIALLY LIFE- THREATENING EMERGENCIES;10
4.1;Thyrotoxicosis;11
4.1.1;INTRODUCTION;11
4.1.2;CAUSES OF THYROTOXICOSIS;12
4.1.3;TOXIC MULTINODULAR GOITER;16
4.1.4;SOLITARY TOXIC ADENOMA (PLUMMER’S DISEASE);17
4.1.5;THYROTOXICOSIS FACTITIA;26
4.1.6;OTHER FORMS OF THYROTOXICOSIS;27
4.1.7;TREATMENT OF THYROTOXICOSIS;29
4.1.8;SURGERY;32
4.2;Myxedema Coma;37
4.2.1;INTRODUCTION;37
4.2.2;EPIDEMIOLOGY;38
4.2.3;CLINICAL PRESENTATION;38
4.2.4;DIAGNOSIS;43
4.2.5;TREATMENT;44
4.2.6;SUMMARY;50
4.3;Acute Adrenal Crisis;53
4.3.1;INTRODUCTION;53
4.3.2;ADRENAL PHYSIOLOGY;54
4.3.3;AETIOLOGY OF ADRENAL INSUFFICIENCY;57
4.3.4;DIAGNOSIS;61
4.3.5;TREATMENT;64
4.3.6;SUMMARY;66
4.4;Acute Calcium Disorders;71
4.4.1;CALCIUM CONCENTRATION IN EXTRACELLULAR FLUIDS;71
4.4.2;PATHOGENESIS AND ETIOLOGY OF HYPER- AND HYPOCALCEMIA;73
4.4.3;DIAGNOSTIC PROCEDURES;80
4.4.4;SYMPTOMS AND CLINICAL SPECTRUM OF HYPER- AND HYPOCALCEMIA ( TABLE 1);81
4.4.5;TREATMENT OF ACUTE HYPERCALCEMIA;82
4.4.6;TREATMENT OF ACUTE HYPOCALCEMIA;87
4.5;Phaeochromocytoma and Other Diseases of the Sympathetic Nervous System;92
4.5.1;BASIC PRINCIPLES;92
4.5.2;PHAEOCHROMOCYTOMA AND PARAGANGLIOMA;97
4.5.3;INVESTIGATIONS;107
4.5.4;MANAGEMENT;111
4.5.5;SUMMARY;116
4.6;Hyperglycemic Crises: Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar State ( HHS);126
4.6.1;PRECIPITATING CAUSES;130
4.6.2;PATHOGENESIS OF DIABETIC KETOACIDOSIS AND HYPERGLYCEMIC HYPEROSMOLAR STATE;130
4.6.3;RESOLUTION OF DKA AND HHS;147
4.6.4;COMPLICATIONS;148
4.6.5;PREVENTION;148
4.6.6;PROSPECTIVES AND FUTURE STUDIES;149
4.7;Hypoglycemia: An Endocrine Emergency;155
4.7.1;BACKGROUND;155
4.7.2;DEFINITION, SYMPTOMS, RISK FACTORS, AND CLASSIFICATION;157
4.7.3;ETIOLOGY OF FASTING HYPOGLYCEMIA IN ADULTS;159
4.7.4;AUTO-IMMUNE CAUSES;162
4.7.5;DIAGNOSIS;162
4.7.6;THERAPEUTIC PRINCIPLES;165
4.7.7;SUMMARY;165
5;II ENDOCRINE DISTURBANCES CAUSED BY NON-ENDOCRINE CRITICAL ILLNESSES;171
5.1;The Dynamic Neuroendocrine Response to Critical Illness;172
5.1.1;INTRODUCTION;172
5.1.2;THE SOMATOTROPIC AXIS;173
5.1.3;THE THYROID AXIS;175
5.1.4;THE GONADAL AND LACTOTROPIC AXES;177
5.1.5;THE ADRENAL AXIS;179
5.1.6;CONCLUSIONS;180
5.2;Changes Within the GH/ IGF- I/ IGFBP Axis in Critical Illness;186
5.2.1;THE SOMATOTROPIC AXIS;186
5.2.2;GH SECRETION DURING CRITICAL ILLNESS;190
5.2.3;RELATIONSHIP BETWEEN GH AND THE TERNARY COMPLEX DURING CRITICAL ILLNESS;191
5.2.4;CLINICAL INTERVENTIONS REGARDING THE SOMATOTROPIC AXIS DURING CRITICAL ILLNESS;193
5.2.5;SUMMARY;197
5.3;Changes Within the Thyroid Axis During the Course of Critical Illness;204
5.3.1;INTRODUCTION;204
5.3.2;PERIPHERAL CHANGES DURING CRITICAL ILLNESS;205
5.3.3;NEUROENDOCRINE CHANGES DURING CRITICAL ILLNESS;209
5.3.4;TREATING THE LOW T3 SYNDROME;211
5.4;The Adrenal Response to Critical Illness;219
5.4.1;INTRODUCTION;219
5.4.2;EVIDENCE OF IMPAIRED HYPOTHALAMIC PITUITARY ADRENAL AXIS DURING CRITICAL ILLNESS;220
5.4.3;MECHANISMS OF IMPAIRED HYPOTHALAMIC-PITUITARY ADRENAL RESPONSE TO CRITICAL ILLNESS;221
5.4.4;DIAGNOSIS OF IMPAIRED HYPOTHALAMIC PITUITARY ADRENAL AXIS DURING CRITICAL ILLNESS;224
5.4.5;CLINICAL CONSEQUENCES OF CRITICAL ILLNESS ASSOCIATED IMPAIRED HPA AXIS;225
5.4.6;TREATMENT WITH GLUCOCORTICOIDS DURING CRITICAL ILLNESS;226
5.4.7;CONCLUSION;228
5.5;Catecholamines and Vasopressin During Critical Illness;232
5.5.1;INTRODUCTION;233
5.5.2;CLINICAL PHARMACOLOGY AND PRACTICAL USE OF CATECHOLAMINES;233
5.5.3;CATECHOLAMINES AND REGIONAL PERFUSION;235
5.5.4;IMMUNE MODULATION BY CATECHOLAMINES;240
5.5.5;VASOPRESSIN AND ITS ANALOGOUS IN SHOCK THERAPY;241
5.5.6;HEMODYNAMIC EFFECTS OF VASOPRESSIN IN SEPTIC SHOCK: EXPERIMENTAL STUDIES;242
5.5.7;V1 AGONISTS IN SEPTIC SHOCK: CLINICAL STUDIES IN ADULT PATIENTS;243
5.5.8;EFFECTS OF V1 AGONISTS ON SPLANCHNIC CIRCULATION: EXPERIMENTAL STUDIES;245
5.5.9;EFFECTS OF V1 AGONISTS ON RENAL: EXPERIMENTAL STUDIES;247
5.5.10;EFFECTS OF V1 AGONISTS ON REGIONAL CIRCULATIONS DURING SEPTIC SHOCK: CLINICAL STUDIES;247
5.5.11;CONCLUSION;249
5.6;The Diabetes of Injury: Novel Insights and Clinical Implications;258
5.6.1;INTRODUCTION;259
5.6.2;INTENSIVE INSULIN THERAPY TO THE TARGET OF NORMOGLYCEMIA IN CRITICAL ILLNESS: THE LEUVEN STUDIES;259
5.6.3;OTHER STUDIES ON INTENSIVE INSULIN THERAPY IN CRITICAL ILLNESS;262
5.6.4;WHAT SHOULD BE THE TARGET OF GLUCOSE CONTROL WITH INTENSIVE INSULIN THERAPY?;264
5.6.5;FEAR FOR HYPOGLYCEMIA: DOES IT OUTWEIGH THE CLINICAL BENEFITS OF INTENSIVE INSULIN THERAPY?;265
5.6.6;DO ALL PATIENTS BENEFIT FROM INTENSIVE INSULIN THERAPY?;266
5.6.7;COULD HIGH-DOSE INSULIN ADMINISTRATION HARM THE CRITICALLY ILL PATIENT?;267
5.6.8;PRACTICAL CONSIDERATIONS WHEN IMPLEMENTING TIGHT GLYCEMIC CONTROL;268
5.6.9;HOW DOES INTENSIVE INSULIN THERAPY IMPROVE OUTCOME FROM CRITICAL ILLNESS?;269
5.6.10;CONCLUSION;273
5.7;Disorders of Body Water Homeostasis;280
5.7.1;INTRODUCTION;280
5.7.2;OVERVIEW OF NORMAL WATER METABOLISM;281
5.7.3;HYPONATREMIA;281
5.7.4;HYPERNATREMIA;296
5.7.5;SUMMARY;302
6;Index;308
INTRODUCTION
Critical illness is characterized by a uniform dysregulation of all hypothalamic–anterior-pituitary axes. These neuroendocrine alterations contribute to the high risk of morbidity and mortality in the intensive care unit. Through recent research, it has become clear that the neuroendocrine response is substantially different in the acute and prolonged phase of critical illness (1,2). The acute phase is exemplified by low peripheral effector hormone levels, despite an actively secreting pituitary. In prolonged critical illness, a uniform suppression of the neuroendocrine axes, primarily of hypothalamic origin, contributes to the low levels of peripheral effector hormones.
The erroneously extrapolation of the changes observed in the acute-disease state to the chronic phase of critical illness has deluded investigators to use certain endocrine treatments with an unexpectedly increased mortality in consequence (3,4). Therefore, a thorough understanding of the pathophysiology underlying these neuroendocrine changes is essential. Moreover, before considering therapeutic intervention, it is important to differentiate between beneficial and harmful neuroendocrine responses to critical illness.
The endocrine alterations in the acute phase of illness appear to direct to reduce energy and substrate expenditure, thereby pushing back costly anabolism and forcing the substrates released to vital tissues in order to improve survival. This hypercatabolic reaction is likely beneficial and, currently, there is no supportive evidence to intervene. In contrast, the chronic phase of critical illness suffers from persistent hypercatabolism despite feeding, which leads to substantial loss of lean body mass and often concomitant fatty infiltration of vital organs, which may compromise vital functions and delay recovery. Therefore, therapeutic interventions to correct these alterations may open perspectives to improved survival.
THE SOMATOTROPIC AXIS
Growth hormone (GH) is secreted by the somatotropes in the pituitary in a pulsatile fashion. It is essential for linear growth during childhood, but has many more functions throughout life, mostly anabolic. The regulation of the physiological pulsatile release of GH, with peaks followed by undetectable levels, is important for its metabolic effects (5). Hypothalamic GH-releasing hormone (GHRH) stimulates and somatostatin inhibits GH secretion. Also several synthetic GH-releasing peptides (GHRPs) and non-peptide analogues with potent GH-releasing activity have been developed (6). These GHRPs act via a G-protein-coupled receptor which is located in the hypothalamus and the pituitary (7). The highly conserved ghrelin is an endogenous ligand for this receptor, and appears to be a third key factor in the physiological control of GH release (8). The indirect actions of GH are regulated mainly through stimulation of insulin-like growth factor-I (IGF-I) production, of which the bio-activity in turn is controlled by several IGF-binding proteins (IGFBPs).
The Somatotropic Axis in Acute Illness
The acute phase of illness, in the first hours to days after an acute insult, is hallmarked by a dramatically changed GH profile. The number of GH bursts is increased, peak GH levels are elevated and inter-pulse concentrations are high (1,9).




